Overview

Raloxifene Use for The Heart

Status:
Completed

Trial end date:
2005-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether raloxifene compared with placebo lowers the risk of coronary events and reduces the risk of invasive breast cancer in postmenopausal women at risk for major coronary events.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Raloxifene Hydrochloride